Who are Epanova's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Omega-3 fatty acid capsules, Omacor + simvastatin, Eicosapentaenoic acid ethyl ester, Product 3 - Standard Fish Oil Triglyceride, fenofibrate/omega, THYROX (Atlantic krill oil)..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omega-3-carboxylic-acids.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Epanova — Competitive Intelligence Brief

Epanova (OMEGA-3-CARBOXYLIC ACIDS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 Fatty Acid. Area: Metabolic.

marketed Omega-3 Fatty Acid Metabolic Live · refreshed every 30 min

Target snapshot

Epanova (OMEGA-3-CARBOXYLIC ACIDS) — AstraZeneca.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epanova TARGET	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
Omega-3 fatty acid capsules	Omega-3 fatty acid capsules	Medical Center Alkmaar	marketed	Omega-3 fatty acid supplement
Omacor + simvastatin	Omacor + simvastatin	Provident Clinical Research	marketed	Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin)	VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin)
Eicosapentaenoic acid ethyl ester	Eicosapentaenoic acid ethyl ester	Yamaguchi University Hospital	marketed	Omega-3 fatty acid / Triglyceride-lowering agent
Product 3 - Standard Fish Oil Triglyceride	Product 3 - Standard Fish Oil Triglyceride	RDC Clinical Pty Ltd	marketed	Omega-3 fatty acid supplement
fenofibrate/omega	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)
THYROX (Atlantic krill oil).	THYROX (Atlantic krill oil).	Poznan University of Physical Education	marketed	Dietary supplement / Omega-3 fatty acid supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 Fatty Acid class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epanova — Competitive Intelligence Brief. https://druglandscape.com/ci/omega-3-carboxylic-acids. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab